YOLFTbeta
Ouro Fino Saúde Animal Participações S.A

Ouro Fino Saúde Animal Participações S.A

OFSA3 · SA · Healthcare / Drug Manufacturers - Specialty & Generic

27.10BRL+0.10 (+0.37%)

Price History

Full chart

Market Stats

Previous Close27.00
Open27.90
Day Range26.71 – 27.90
52-Week Range20.06 – 34.69
Volume5.90K
Market Cap1.53B
P/E (TTM)6.47
Forward P/E0.00
EPS4.39
Dividend Yield4.63%
Beta0.29
50-Day Avg26.29
200-Day Avg27.00

About

Ouro Fino Saúde Animal Participações S.A., together with its subsidiaries, engages in the development, production, and sale of veterinary drugs, vaccines, and other products for production and companion animals primarily in Brazil. The company operates through three segments: Production Animals; Companion Animals; and International Operations. It manufactures and trades in medicines, including anti-inflammatories, antibiotics, anticoccidials, antimastitics, ectoparasiticides, endectocides, endoparasiticides, hemoparasiticides, inoculants, therapeutics, products for animal reproduction, and vaccines; and performance-enhancing additives, probiotics, and other veterinary products for cattle, swine, poultry, sheep, horses, and goats, as well as manufacturing services. The company also manufactures veterinary solutions for dogs and cats, such as anesthetics, sedatives, anti-inflammatory, antibiotic, antimicrobial, dermatological, ectoparasiticide, endoparasiticide, dermocosmetic, and otological products. In addition, it offers vaccines and other veterinary products for production and companion animals. The company was formerly known as A.H.N.S.P.E. Empreendimentos e Participações S.A. Ouro Fino Saúde Animal Participações S.A. was incorporated in 1987 and is headquartered in Cravinhos, Brazil.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEOMr. Kleber Cesar Silveira Gomes
  • Employees1.09K
  • HeadquartersRodovia Anhanguera SP 330, Cravinhos, SP, Brazil, 14140-000, Brazil
  • Websitehttps://www.ourofinosaudeanimal.com

Leadership

  • Mr. Kleber Cesar Silveira GomesCEO & Member of Executive Board · b. 1975
  • Mr. Marcelo Da SilvaCFO, Member of Executive Board & Chief Investor Relations Officer · b. 1979
  • Mr. Tetsuhiko HiramatsuMember of Executive Board · b. 1973
  • Angelo MeloDirector - Strategic Development & New Business
  • Bruno MenegazzoSupervisor of the Investor Relations Area

Financials

Income Statement

Currency: BRL2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue296.07M320.21M384.02M327.36M534.04M456.59M505.28M589.22M619.59M730.11M904.99M1.04B943.28M1.02B1.22B
Growth (%)-+8.15%+19.93%-14.75%+63.14%-14.50%+10.66%+16.61%+5.15%+17.84%+23.95%+15.04%-9.40%+8.64%+19.54%
Cost of Revenue100.56M116.57M138.75M124.39M236.28M226.78M237.72M265.04M311.85M356.12M457.73M513.03M510.47M507.11M591.98M
Gross Profit---241.50M297.77M229.80M267.56M324.18M307.74M373.99M447.26M528.08M432.81M517.68M633.02M
Gross Margin---73.77%55.76%50.33%52.95%55.02%49.67%51.22%49.42%50.72%45.88%50.52%51.68%
Operating Expense---179.47M201.31M220.95M201.21M226.21M235.94M271.87M306.15M350.76M351.80M-349.20M396.54M
Operating Income63.82M54.62M66.44M62.03M96.45M8.85M66.35M97.97M71.80M102.12M141.11M177.32M81.01M866.89M236.47M
Operating Margin21.55%17.06%17.30%18.95%18.06%1.94%13.13%16.63%11.59%13.99%15.59%17.03%8.59%84.59%19.30%
EBITDA------88.84M125.34M95.74M134.15M173.00M216.51M128.03M246.27M290.53M
EBITDA Margin------17.58%21.27%15.45%18.37%19.12%20.80%13.57%24.03%23.72%
Net Income---51.21M69.19M-5.21M38.11M68.85M46.28M89.72M113.96M130.66M-49.98M814.39M222.31M
Net Income Margin---15.64%12.96%-1.14%7.54%11.68%7.47%12.29%12.59%12.55%-5.30%79.47%18.15%
R&D1.81M1.95M2.14M27.10M-13.70M13.00M--39.67M58.93M69.34M59.70M49.45M59.95M
R&D as % of Total Revenue0.61%0.61%0.56%8.28%-3.00%2.57%--5.43%6.51%6.66%6.33%4.83%4.89%
Interest Expense000000016.98M13.15M13.91M19.63M37.45M3.54M31.49M32.96M
Interest Expense % of Total Revenue0.00%0.00%0.00%0.00%0.00%0.00%0.00%2.88%2.12%1.91%2.17%3.60%0.38%3.07%2.69%

Balance Sheet

Currency: BRL2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets465.91M452.13M538.68M627.26M693.37M775.58M810.23M846.01M869.54M1.10B1.19B1.35B1.28B1.38B1.57B
Total Liabilities288.47M257.30M329.26M297.10M313.06M399.24M404.35M390.07M377.09M543.16M551.20M610.55M589.61M628.31M768.97M
Total Equity177.41M194.80M209.38M330.07M380.18M376.33M405.88M455.94M492.45M560.78M641.45M735.95M689.37M756.40M796.84M
Cash35.70M15.78M38.42M72.45M23.38M70.33M123.36M65.18M45.01M225.57M161.25M14.11M304.03M10.70M250.82M
Total Debt-----315.44M285.51M244.79M277.19M297.79M-----
Net Debt---------168.76M221.12M247.33M127.94M125.40M238.76M

Cash Flow

Currency: BRL2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow14.10M33.13M33.45M853.00K15.51M42.24M99.50M42.81M56.39M111.94M46.50M89.59M190.30M73.94M99.91M
Investing Cash Flow----24.49M-56.00M-83.97M-25.24M-46.41M-50.40M-23.53M-60.41M-78.15M-37.14M-42.88M-41.77M
Financing Cash Flow53.76M-26.56M75.91M-8.76M89.88M-21.22M-54.77M-26.30M91.52M-50.62M-7.95M-14.36M-102.17M-40.65M
Capital Expenditure14.42M15.12M27.57M14.27M35.05M85.25M31.85M48.32M52.13M24.52M55.91M51.97M47.68M44.70M47.32M
Free Cash Flow------67.66M-5.52M4.26M87.41M-19.68M19.41M142.62M29.24M52.60M
Dividends Paid10.53M11.67M35.75M9.11M12.89M16.43M10.85M10.85M16.35M10.99M35.61M33.22M23.41M18.17M35.00M
FCF to OCF------67.99%-12.89%7.55%78.09%-42.33%21.67%74.95%39.55%52.64%
Dividend Paid to FCF------16.03%-196.65%383.92%12.57%-180.91%171.13%16.41%62.13%66.54%

Earnings

Report DateNov 19, 2014Mar 25, 2015Jun 3, 2015Aug 12, 2015Oct 26, 2015Mar 22, 2016May 10, 2016Aug 9, 2016Nov 14, 2016Mar 21, 2017May 9, 2017Aug 8, 2017Nov 9, 2017Mar 6, 2018May 8, 2018Aug 7, 2018Nov 6, 2018Mar 19, 2019May 7, 2019Aug 7, 2019Nov 5, 2019Feb 11, 2020May 12, 2020Aug 6, 2020Nov 9, 2020Mar 29, 2021May 6, 2021Aug 5, 2021Nov 11, 2021Feb 25, 2022May 12, 2022Aug 5, 2022May 9, 2023Aug 9, 2023Nov 8, 2023Mar 6, 2024
EPS Estimate-0.28--0.300.43-0.160.270.07-0.120.210.290.350.040.300.29-0.050.390.470.59-0.090.540.37--0.080.410.62---0.180.340.430.77
EPS Actual0.220.380.140.350.350.44-0.060.110.14-0.15-0.130.240.250.420.070.450.410.35-0.100.260.230.45-0.060.270.840.590.180.590.640.700.300.44-0.06-1.310.080.37
Surprise-35.71%--16.67%2.33%--31.25%-48.15%-314.29%-8.33%14.29%-13.79%20.00%75.00%50.00%41.38%--300.00%-33.33%-51.06%-23.73%33.33%-50.00%127.03%-325.00%43.90%3.23%----133.33%-485.29%-81.40%-51.95%
TimingPre-marketAfter-hours--After-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hours

Key Statistics & Ratios

Market Cap1.53B
Enterprise Value1.53B
Trailing P/E6.47
Forward P/E0.00
Price / Sales1.12
Price / Book1.67
EPS4.39
Book Value15.38
Revenue (TTM)1.37B
Gross Profit (TTM)710.23M
EBITDA302.70M
Profit Margin17.29%
Operating Margin16.25%
Return on Equity31.81%
Return on Assets11.98%
Shares Outstanding53.77M
Shares Float7.28M
Beta0.29
Dividend Yield4.63%
Dividend Rate1.29
Payout Ratio29.38%

Dividends

20252×
0.93Dec 23, 20250.15Apr 17, 2025
20242×
0.58Dec 20, 20240.34Apr 29, 2024
20231×
0.20Apr 14, 2023
20222×
0.44Dec 16, 20220.24Apr 20, 2022
20212×
0.30Dec 17, 20210.17Apr 9, 2021
20202×
0.25Dec 23, 20200.19Oct 14, 2020
20192×
0.02Dec 19, 20190.18Mar 29, 2019
20183×
0.14Dec 14, 20180.03Apr 16, 20180.10Apr 13, 2018
20171×
0.11Dec 19, 2017
20161×
0.22Apr 29, 2016
20153×
0.09Dec 21, 20150.18Apr 28, 20150.07Jan 2, 2015